Incurix announced today that it made an agreement with National OncoVenture (NOV) of the National Cancer Center (NCC) for cooperation in research and development of c-myc inhibitor ‘ICX-101’. ICX-101, the program on which the joint research agreement was made, is a candidate substance Incurix in-licensed from the National Cancer Center (NCC) and the Korea Research Institute of Chemical Technology (KRICT) in April. The c-myc protein, the target of ICX-101, is cell proliferation- and death-mediated transcription factor. The c-myc protein is key to the occurrence, growth and metastasis of cancer, and is over-expressed in various cancers, such as hematologic malignancy, lung cancer, breast cancer and central nervous system tumor.

“Although the c-myc is an important target in anti-cancer drug development, no drug of c-myc target has been developed yet because of technological problems,” Incurix CEO Kyung-Chae Jeong said. He added, “We will develop ICX-101 in partnership with National OncoVenture.”

http://www.biospectator.com/view/news_view.php?varAtcId=11283